Header Logo

Connection

Elizabeth Evans to Humans

Back to Details
This is a "connection" page, showing publications Elizabeth Evans has written about Humans.
Elizabeth Evans
Connection Strength
1.530
Humans
  1. Pivovarova E, Planas Garcia BY, Friedmann PD, Stopka TJ, Santelices C, Evans EA. Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. J Addict Med. 2025 Jan-Feb 01; 19(1):95-101.
    View in: PubMed
    Score: 0.036
  2. Evans E, Jacobs M, Ellis C. Allostatic load and cognitive recall among young adults: Racial, ethnic, and sex-specific variations. J Int Neuropsychol Soc. 2024 Oct; 30(8):755-763.
    View in: PubMed
    Score: 0.036
  3. Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.
    View in: PubMed
    Score: 0.036
  4. Evans E, Jacobs M. Diabetes and Financial Well-Being: Differential Hardship Among Vulnerable Populations. Sci Diabetes Self Manag Care. 2024 Aug; 50(4):263-274.
    View in: PubMed
    Score: 0.035
  5. Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 Dec; 122:104252.
    View in: PubMed
    Score: 0.034
  6. Senthilkumar R, Bailey A, Moner E, Parduhn T, Evans EA. Lessons Learned from Implementation of a Post-opioid Overdose Outreach Program in a Rural Massachusetts Community. Community Ment Health J. 2024 04; 60(3):482-493.
    View in: PubMed
    Score: 0.034
  7. Bailey A, Taylor BG, Pollack HA, Schneider JA, Evans EA. Gender identity, stimulant drug use, and criminal justice history on internalized stigma among a nationally representative sample of adults who misuse opioids. Soc Psychiatry Psychiatr Epidemiol. 2024 Feb; 59(2):305-313.
    View in: PubMed
    Score: 0.033
  8. Klemperer EM, Wreschnig L, Crocker A, King-Mohr J, Ramniceanu A, Brooklyn JR, Peck KR, Rawson RA, Evans EA. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose. J Subst Use Addict Treat. 2023 09; 152:209103.
    View in: PubMed
    Score: 0.033
  9. Bailey A, Senthilkumar R, Evans EA. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail. J Addict Med. 2023 Sep-Oct 01; 17(5):568-573.
    View in: PubMed
    Score: 0.033
  10. Evans EA, Geissler KH. Use of Big Data and Ethical Issues for Populations With Substance Use Disorder. Value Health. 2023 09; 26(9):1321-1324.
    View in: PubMed
    Score: 0.032
  11. Bailey A, Evans EA. Holyoke Early Access to Recovery and Treatment (HEART): A case study of a court-based intervention to reduce opioid overdose. J Ethn Subst Abuse. 2024 Oct-Dec; 23(4):1039-1061.
    View in: PubMed
    Score: 0.032
  12. Harrington C, Bailey A, Delorme E, Hano S, Evans EA. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19. Subst Use Misuse. 2023; 58(2):266-274.
    View in: PubMed
    Score: 0.032
  13. Stopka TJ, Rottapel RE, Ferguson WJ, Pivovarova E, Toro-Mejias LD, Friedmann PD, Evans EA. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. Int J Drug Policy. 2022 Dec; 110:103803.
    View in: PubMed
    Score: 0.031
  14. Fiddian-Green A, Gubrium A, Harrington C, Evans EA. Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder. Int J Environ Res Public Health. 2022 07 30; 19(15).
    View in: PubMed
    Score: 0.031
  15. Evans EA. Commentary on Adams et al.: using administrative big data for the public good. Addiction. 2022 10; 117(10):2649-2650.
    View in: PubMed
    Score: 0.031
  16. Evans EA, Pivovarova E, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. J Subst Abuse Treat. 2022 07; 138:108746.
    View in: PubMed
    Score: 0.030
  17. Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022 02 01; 231:109254.
    View in: PubMed
    Score: 0.030
  18. Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021 09; 128:108275.
    View in: PubMed
    Score: 0.028
  19. Donelan CJ, Hayes E, Potee RA, Schwartz L, Evans EA. COVID-19 and treating incarcerated populations for opioid use disorder. J Subst Abuse Treat. 2021 05; 124:108216.
    View in: PubMed
    Score: 0.028
  20. Evans EA, Harrington C, Roose R, Lemere S, Buchanan D. Perceived Benefits and Harms of Involuntary Civil Commitment for Opioid Use Disorder. J Law Med Ethics. 2020 12; 48(4):718-734.
    View in: PubMed
    Score: 0.028
  21. Evans EA, Goldwater E, Stanek EJ, Brierley-Bowers P, Buchanan D, Whitehill JM. Prevalence and Correlates of Cannabis Use in Massachusetts after Cannabis Legalization and before Retail Sales. J Psychoactive Drugs. 2021 Apr-Jun; 53(2):158-167.
    View in: PubMed
    Score: 0.028
  22. Evans EA, Delorme E, Cyr K, Goldstein DM. A qualitative study of big data and the opioid epidemic: recommendations for data governance. BMC Med Ethics. 2020 10 21; 21(1):101.
    View in: PubMed
    Score: 0.027
  23. Evans EA, Sayers SR, Kodji X, Xia Y, Shaikh M, Rizvi A, Frame J, Brain SD, Philpott MP, Hannen RF, Caton PW. Psoriatic skin inflammation induces a pre-diabetic phenotype via the endocrine actions of skin secretome. Mol Metab. 2020 11; 41:101047.
    View in: PubMed
    Score: 0.027
  24. Geissler KH, Evans EA. Changes in Medicaid Acceptance by Substance Abuse Treatment Facilities After Implementation of Federal Parity. Med Care. 2020 02; 58(2):101-107.
    View in: PubMed
    Score: 0.026
  25. Evans EA, Goff SL, Upchurch DM, Grella CE. Childhood adversity and mental health comorbidity in men and women with opioid use disorders. Addict Behav. 2020 03; 102:106149.
    View in: PubMed
    Score: 0.025
  26. Evans EA, Yoo C, Huang D, Saxon AJ, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2?years: Results from a multisite randomized trial of adults with opioid use disorder. J Subst Abuse Treat. 2019 11; 106:19-28.
    View in: PubMed
    Score: 0.025
  27. Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019 08; 114(8):1396-1404.
    View in: PubMed
    Score: 0.025
  28. Evans EA, Herman PM, Washington DL, Lorenz KA, Yuan A, Upchurch DM, Marshall N, Hamilton AB, Taylor SL. Gender Differences in Use of Complementary and Integrative Health by U.S. Military Veterans with Chronic Musculoskeletal Pain. Womens Health Issues. 2018 Sep - Oct; 28(5):379-386.
    View in: PubMed
    Score: 0.024
  29. Evans EA, Glover DL, Washington DL, Hamilton AB. Psychosocial Factors that Shape Substance Abuse and Related Mental Health of Women Military Veterans who Use Community-Based Services. Subst Use Misuse. 2018 09 19; 53(11):1878-1892.
    View in: PubMed
    Score: 0.023
  30. Evans EA, Upchurch DM, Simpson T, Hamilton AB, Hoggatt KJ. Differences by Veteran/civilian status and gender in associations between childhood adversity and alcohol and drug use disorders. Soc Psychiatry Psychiatr Epidemiol. 2018 04; 53(4):421-435.
    View in: PubMed
    Score: 0.022
  31. Evans EA, Grella CE, Washington DL, Upchurch DM. Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. Drug Alcohol Depend. 2017 05 01; 174:128-136.
    View in: PubMed
    Score: 0.021
  32. Evans EA, Grella CE, Upchurch DM. Gender differences in the effects of childhood adversity on alcohol, drug, and polysubstance-related disorders. Soc Psychiatry Psychiatr Epidemiol. 2017 07; 52(7):901-912.
    View in: PubMed
    Score: 0.021
  33. Evans EA, Perkins E, Clarke P, Haines A, Baldwin A, Whittington R. Care home manager attitudes to balancing risk and autonomy for residents with dementia. Aging Ment Health. 2018 Feb; 22(2):261-269.
    View in: PubMed
    Score: 0.021
  34. Evans E, Padwa H, Li L, Lin V, Hser YI. Heterogeneity of Mental Health Service Utilization and High Mental Health Service Use Among Women Eight Years After Initiating Substance Use Disorder Treatment. J Subst Abuse Treat. 2015 Dec; 59:10-9.
    View in: PubMed
    Score: 0.019
  35. Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015 Jun; 110(6):996-1005.
    View in: PubMed
    Score: 0.019
  36. Evans E, Li L, Buoncristiani S, Hser YI. Perceived neighborhood safety, recovery capital, and successful outcomes among mothers 10 years after substance abuse treatment. Subst Use Misuse. 2014 Sep; 49(11):1491-503.
    View in: PubMed
    Score: 0.018
  37. Evans E, Li L, Pierce J, Hser YI. Explaining long-term outcomes among drug dependent mothers treated in women-only versus mixed-gender programs. J Subst Abuse Treat. 2013 Sep; 45(3):293-301.
    View in: PubMed
    Score: 0.016
  38. Anglin MD, Nosyk B, Jaffe A, Urada D, Evans E. Offender diversion into substance use disorder treatment: the economic impact of California's proposition 36. Am J Public Health. 2013 Jun; 103(6):1096-102.
    View in: PubMed
    Score: 0.016
  39. Evans E, Li L, Grella C, Brecht ML, Hser YI. Developmental timing of first drug treatment and 10-year patterns of drug use. J Subst Abuse Treat. 2013 Mar; 44(3):271-9.
    View in: PubMed
    Score: 0.016
  40. Evans E, Pierce J, Li L, Rawson R, Hser YI. More alike than different: health needs, services utilization, and outcomes of Asian American and Pacific Islander (AAPI) populations treated for substance use disorders. J Ethn Subst Abuse. 2012; 11(4):318-38.
    View in: PubMed
    Score: 0.015
  41. Evans E, Huang D, Hser YI. High-risk offenders participating in court-supervised substance abuse treatment: characteristics, treatment received, and factors associated with recidivism. J Behav Health Serv Res. 2011 Oct; 38(4):510-25.
    View in: PubMed
    Score: 0.015
  42. Evans E, Anglin MD, Urada D, Yang J. Promising practices for delivery of court-supervised substance abuse treatment: perspectives from six high-performing California counties operating Proposition 36. Eval Program Plann. 2011 May; 34(2):124-34.
    View in: PubMed
    Score: 0.014
  43. Evans E, Hser YI, Huang D. Employment services utilization and outcomes among substance abusing offenders participating in California's proposition 36 drug treatment initiative. J Behav Health Serv Res. 2010 Oct; 37(4):461-76.
    View in: PubMed
    Score: 0.013
  44. Evans E, Li L, Hser YI. Client and program factors associated with dropout from court mandated drug treatment. Eval Program Plann. 2009 Aug; 32(3):204-12.
    View in: PubMed
    Score: 0.012
  45. Evans E, Grella CE, Murphy DA, Hser YI. Using administrative data for longitudinal substance abuse research. J Behav Health Serv Res. 2010 Apr; 37(2):252-71.
    View in: PubMed
    Score: 0.012
  46. Evans E, Li L, Hser YI. Treatment entry barriers among California's Proposition 36 offenders. J Subst Abuse Treat. 2008 Dec; 35(4):410-8.
    View in: PubMed
    Score: 0.012
  47. Hser YI, Evans E. Cross-system data linkage for treatment outcome evaluation: lessons learned from the California Treatment Outcome Project. Eval Program Plann. 2008 May; 31(2):125-35.
    View in: PubMed
    Score: 0.011
  48. Hser YI, Huang D, Brecht ML, Li L, Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis. 2008; 27(3):13-21.
    View in: PubMed
    Score: 0.011
  49. Evans E, Longshore D, Prendergast M, Urada D. Evaluation of the Substance Abuse and Crime Prevention Act: client characteristics, treatment completion and re-offending three years after implementation. J Psychoactive Drugs. 2006 Nov; Suppl 3:357-67.
    View in: PubMed
    Score: 0.010
  50. Evans E, Spear SE, Huang YC, Hser YI. Outcomes of drug and alcohol treatment programs among American Indians in California. Am J Public Health. 2006 May; 96(5):889-96.
    View in: PubMed
    Score: 0.010
  51. Teruya C, Hardy M, Hser YI, Evans E. Implementation of a statewide outcome monitoring system: lessons learned from substance abuse treatment provider staff. Qual Health Res. 2006 Mar; 16(3):337-52.
    View in: PubMed
    Score: 0.010
  52. Michener PS, Bianchet E, Fox S, Evans EA, Friedmann PD. "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder. Harm Reduct J. 2024 07 22; 21(1):138.
    View in: PubMed
    Score: 0.009
  53. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.
    View in: PubMed
    Score: 0.009
  54. Jacobs MM, Evans E, Ellis C. Financial Well-Being Among US Adults with Vascular Conditions: Differential Impacts Among Blacks and Hispanics. Ethn Dis. 2024 Jan; 34(1):41-48.
    View in: PubMed
    Score: 0.009
  55. Evans E, Hser YI. Pilot-testing a statewide outcome monitoring system: overview of the California Treatment Outcome Project (CALTOP). J Psychoactive Drugs. 2004 May; Suppl 2:109-14.
    View in: PubMed
    Score: 0.009
  56. Evans E, Longshore D. Evaluation of the substance abuse and crime prevention act: treatment clients and program types during the first year of implementation. J Psychoactive Drugs. 2004 May; Suppl 2:165-74.
    View in: PubMed
    Score: 0.009
  57. Jacobs M, Evans E, Ellis C. Exploring the association between social determinants and aphasia impairment: A retrospective data integration approach. PLoS One. 2024; 19(3):e0299979.
    View in: PubMed
    Score: 0.009
  58. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.
    View in: PubMed
    Score: 0.009
  59. Evans EA, Jeste DV. William Carlos Williams. Am J Geriatr Psychiatry. 2004 Mar-Apr; 12(2):129-33; discussion 128.
    View in: PubMed
    Score: 0.009
  60. Michener PS, Evans EA, Ferguson WJ, Friedmann PD. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives. Addict Sci Clin Pract. 2024 02 12; 19(1):10.
    View in: PubMed
    Score: 0.009
  61. Klemperer EM, Evans EA, Rawson R. A call to action: Contingency management to improve post-release treatment engagement among people with opioid use disorder who are incarcerated. Prev Med. 2023 Nov; 176:107647.
    View in: PubMed
    Score: 0.008
  62. Videka L, Page C, Buche J, Neale J, Evans E, Beck AJ, Grazier KL, Railey JA, Gaiser M. Peer Support Services in Behavioral Health Facilities: Secondary Analysis From Two National Surveys. Psychiatr Serv. 2023 Dec 01; 74(12):1247-1255.
    View in: PubMed
    Score: 0.008
  63. Jacobs MM, Evans E, Ellis C. Racial, ethnic, and sex disparities in the incidence and cognitive symptomology of long COVID-19. J Natl Med Assoc. 2023 Apr; 115(2):233-243.
    View in: PubMed
    Score: 0.008
  64. Matsumoto A, Santelices C, Evans EA, Pivovarova E, Stopka TJ, Ferguson WJ, Friedmann PD. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. Int J Drug Policy. 2022 11; 109:103823.
    View in: PubMed
    Score: 0.008
  65. Goodsmith N, Cohen AN, Pedersen ER, Evans E, Young AS, Hamilton AB. Predictors of Functioning and Recovery Among Men and Women Veterans with Schizophrenia. Community Ment Health J. 2023 01; 59(1):110-121.
    View in: PubMed
    Score: 0.008
  66. Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022 05 01; 234:109394.
    View in: PubMed
    Score: 0.008
  67. Baker R, Evans E, Fielden A, Arnott B. Healthcare professionals' perspectives on infant feeding support in paediatric inpatients: single-centre qualitative study. BMJ Paediatr Open. 2021; 5(1):e001247.
    View in: PubMed
    Score: 0.007
  68. Geissler KH, Evans EA, Johnson JK, Whitehill JM. A Scoping Review of Data Sources for the Conduct of Policy-Relevant Substance Use Research. Public Health Rep. 2022 Sep-Oct; 137(5):944-954.
    View in: PubMed
    Score: 0.007
  69. Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021 11 01; 228:108996.
    View in: PubMed
    Score: 0.007
  70. Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022 01; 117(1):151-161.
    View in: PubMed
    Score: 0.007
  71. Barnett A, Edwards K, Harper R, Evans E, Alexander D, Choudhary M, Richards G. The Association Between Autistic Traits and Disordered Eating is Moderated by Sex/Gender and Independent of Anxiety and Depression. J Autism Dev Disord. 2021 Jun; 51(6):1866-1879.
    View in: PubMed
    Score: 0.007
  72. Jaaniste T, Yang J, Bang J, Yee RD, Evans E, Aouad P, Champion GD. Multidimensional Self-report Assessment of Children's Acute Pain in an Inpatient Setting. Clin J Pain. 2021 06 01; 37(6):421-428.
    View in: PubMed
    Score: 0.007
  73. Montgomery L, Friedmann P, Abraham A, Evans E, Glass J, Ilgen M. Editorial: Health equity in substance use disorder treatment. J Subst Abuse Treat. 2020 11; 118:108101.
    View in: PubMed
    Score: 0.007
  74. Friedmann PD, Abraham A, Evans E, Glass J, Ilgen M, Montgomery L. Editorial: COVID-19 and its impact on SUD treatment. J Subst Abuse Treat. 2020 10; 117:108091.
    View in: PubMed
    Score: 0.007
  75. Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018 12; 13(4):488-497.
    View in: PubMed
    Score: 0.006
  76. Krebs E, Enns B, Evans E, Urada D, Anglin MD, Rawson RA, Hser YI, Nosyk B. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. Ann Intern Med. 2018 01 02; 168(1):10-19.
    View in: PubMed
    Score: 0.006
  77. Caton PW, Evans EA, Philpott MP, Hannen RF. Can the skin make you fat? A role for the skin in regulating adipose tissue function and whole-body glucose and lipid homeostasis. Curr Opin Pharmacol. 2017 12; 37:59-64.
    View in: PubMed
    Score: 0.006
  78. Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, Hser YI, Nosyk B. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017 11; 49:32-40.
    View in: PubMed
    Score: 0.006
  79. Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B. The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. Addiction. 2017 May; 112(5):838-851.
    View in: PubMed
    Score: 0.005
  80. Krebs E, Min JE, Evans E, Li L, Liu L, Huang D, Urada D, Kerr T, Hser YI, Nosyk B. Estimating State Transitions for Opioid Use Disorders. Med Decis Making. 2017 07; 37(5):483-497.
    View in: PubMed
    Score: 0.005
  81. Metz VE, Sullivan MA, Jones JD, Evans E, Luba R, Vogelman J, Comer SD. Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs. 2017 Jan-Mar; 49(1):59-68.
    View in: PubMed
    Score: 0.005
  82. van der Linde RM, Dening T, Stephan BC, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry. 2016 11; 209(5):366-377.
    View in: PubMed
    Score: 0.005
  83. Iacono T, Evans E, Davis A, Bhardwaj A, Turner B, Torr J, Trollor JN. Family caring of older adults with intellectual disability and coping according to loci of responsibility. Res Dev Disabil. 2016 Oct; 57:170-80.
    View in: PubMed
    Score: 0.005
  84. Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016 Apr; 111(4):695-705.
    View in: PubMed
    Score: 0.005
  85. Saroyan JM, Evans EA, Segoshi A, Vosburg SK, Miller-Saultz D, Sullivan MA. Interviewing and Urine Drug Toxicology Screening in a Pediatric Pain Management Center: An Analysis of Analgesic Nonadherence and Aberrant Behaviors in Adolescents and Young Adults. Clin J Pain. 2016 Jan; 32(1):1-6.
    View in: PubMed
    Score: 0.005
  86. Nosyk B, Min JE, Evans E, Li L, Liu L, Lima VD, Wood E, Montaner JS. The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. Clin Infect Dis. 2015 Oct 01; 61(7):1157-65.
    View in: PubMed
    Score: 0.005
  87. Chitty KM, Evans E, Torr JJ, Iacono T, Brodaty H, Sachdev P, Trollor JN. Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study. Aust N Z J Psychiatry. 2016 Apr; 50(4):352-62.
    View in: PubMed
    Score: 0.005
  88. Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015 Mar-Apr; 23(2):76-89.
    View in: PubMed
    Score: 0.005
  89. Hser YI, Evans E, Grella C. Commentary on Degenhardt et?al. (2014): Regional variation in the global burden of disease attributable to opioid dependence-where do the data come from and does population size matter? Addiction. 2014 Aug; 109(8):1334-5.
    View in: PubMed
    Score: 0.004
  90. Nosyk B, Li L, Evans E, Urada D, Huang D, Wood E, Rawson R, Hser YI. Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. Drug Alcohol Depend. 2014 Oct 01; 143:149-57.
    View in: PubMed
    Score: 0.004
  91. Gill KE, Evans E, Kayser J, Ben-David S, Messinger J, Bruder G, Malaspina D, Corcoran CM. Smell identification in individuals at clinical high risk for schizophrenia. Psychiatry Res. 2014 Dec 15; 220(1-2):201-4.
    View in: PubMed
    Score: 0.004
  92. Headley S, Germain M, Wood R, Joubert J, Milch C, Evans E, Poindexter A, Cornelius A, Brewer B, Pescatello LS, Parker B. Short-term aerobic exercise and vascular function in CKD stage 3: a randomized controlled trial. Am J Kidney Dis. 2014 Aug; 64(2):222-9.
    View in: PubMed
    Score: 0.004
  93. Nosyk B, Sun H, Evans E, Marsh DC, Anglin MD, Hser YI, Anis AH. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction. 2012 Sep; 107(9):1621-9.
    View in: PubMed
    Score: 0.004
  94. Eby LT, Sparks TE, Evans E, Selzer JA. A qualitative examination of the positive and negative consequences associated with going tobacco-free in substance abuse treatment: the NY State experience. Nicotine Tob Res. 2012 Dec; 14(12):1407-17.
    View in: PubMed
    Score: 0.004
  95. Hser YI, Hunt SA, Evans E, Chang YJ, Messina NP. Hispanic parenting women in women-only versus mixed-gender drug treatment: a 10-year prospective study. Addict Behav. 2012 Jun; 37(6):729-35.
    View in: PubMed
    Score: 0.004
  96. Hser YI, Kagihara J, Huang D, Evans E, Messina N. Mortality among substance-using mothers in California: a 10-year prospective study. Addiction. 2012 Jan; 107(1):215-22.
    View in: PubMed
    Score: 0.004
  97. Hser YI, Li J, Jiang H, Zhang R, Du J, Zhang C, Zhang B, Evans E, Wu F, Chang YJ, Peng C, Huang D, Stitzer ML, Roll J, Zhao M. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction. 2011 Oct; 106(10):1801-9.
    View in: PubMed
    Score: 0.004
  98. Hser YI, Evans E, Huang D, Messina N. Long-term outcomes among drug-dependent mothers treated in women-only versus mixed-gender programs. J Subst Abuse Treat. 2011 Sep; 41(2):115-23.
    View in: PubMed
    Score: 0.004
  99. Hser YI, Evans E, Huang D, Brecht ML, Li L. Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict Behav. 2008 Dec; 33(12):1581-9.
    View in: PubMed
    Score: 0.003
  100. Brecht ML, Huang D, Evans E, Hser YI. Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug Alcohol Depend. 2008 Aug 01; 96(3):193-201.
    View in: PubMed
    Score: 0.003
  101. Murphy DA, Brecht ML, Herbeck D, Evans E, Huang D, Hser YI. Longitudinal HIV risk behavior among the Drug Abuse Treatment Outcome Studies (DATOS) adult sample. Eval Rev. 2008 Feb; 32(1):83-112.
    View in: PubMed
    Score: 0.003
  102. Brecht ML, Stein J, Evans E, Murphy DA, Longshore D. Predictors of intention to change HIV sexual and injection risk behaviors among heterosexual methamphetamine-using offenders in drug treatment: a test of the AIDS Risk Reduction Model. J Behav Health Serv Res. 2009 Apr; 36(2):247-66.
    View in: PubMed
    Score: 0.003
  103. Fosados R, Evans E, Hser YI. Ethnic differences in utilization of drug treatment services and outcomes among Proposition 36 offenders in California. J Subst Abuse Treat. 2007 Dec; 33(4):391-9.
    View in: PubMed
    Score: 0.003
  104. Hser YI, Evans E, Teruya C, Huang D, Anglin MD. Predictors of short-term treatment outcomes among California's Proposition 36 participants. Eval Program Plann. 2007 May; 30(2):187-96.
    View in: PubMed
    Score: 0.003
  105. Hser YI, Teruya C, Brown AH, Huang D, Evans E, Anglin MD. Impact of California's Proposition 36 on the drug treatment system: treatment capacity and displacement. Am J Public Health. 2007 Jan; 97(1):104-9.
    View in: PubMed
    Score: 0.003
  106. Ettner SL, Huang D, Evans E, Ash DR, Hardy M, Jourabchi M, Hser YI. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"? Health Serv Res. 2006 Feb; 41(1):192-213.
    View in: PubMed
    Score: 0.002
  107. Hser YI, Grella C, Evans E, Huang YC. Utilization and outcomes of mental health services among patients in drug treatment. J Addict Dis. 2006; 25(1):73-85.
    View in: PubMed
    Score: 0.002
  108. Hser YI, Evans E, Huang YC. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. 2005 Jan; 28(1):77-85.
    View in: PubMed
    Score: 0.002
  109. Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004 Jul; 55(7):767-74.
    View in: PubMed
    Score: 0.002
  110. Hser YI, Teruya C, Evans EA, Longshore D, Grella C, Farabee D. Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes. Eval Rev. 2003 Oct; 27(5):479-505.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.